**R&D OPEN INNOVATION AND PORTFOLIO OPTIMIZATION**

Lean Resource Allocation, Next-Generation Partnership Models and Investment Decision Strategies for High Return R&D

APRIL 8-9, 2014 • DOUBLETREE BY HILTON • PHILADELPHIA, PA

**Renowned Industry Experts Unveil New Models and Strategies for Portfolio ROI**

<table>
<thead>
<tr>
<th>Expert Name</th>
<th>Title and Organization</th>
</tr>
</thead>
<tbody>
<tr>
<td>Simon Bateman</td>
<td>Executive Director, Global Strategic Alliance Management, Novartis</td>
</tr>
<tr>
<td>Annlouise Goodermuth</td>
<td>Director, Alliance Management Strategy, External Innovation and Science Policy, Sanofi-Aventis</td>
</tr>
<tr>
<td>Tomasz Sablinski, M.D., Ph.D.</td>
<td>Co-Founder, Chief Executive Officer, Transparency Life Sciences; Managing Director, Head of Clinical Development, Auven Therapeutics</td>
</tr>
<tr>
<td>Cameron Durrant, Ph.D.</td>
<td>President and Chief Executive Officer, ECR Pharmaceuticals</td>
</tr>
<tr>
<td>Kenneth I. Kaitin, Ph.D.</td>
<td>Director, The Tufts Center for the Study of Drug Development</td>
</tr>
<tr>
<td>Troy Norris</td>
<td>Managing Director, Valamont Advisors, LLC</td>
</tr>
<tr>
<td>Standish Fleming</td>
<td>Managing Member, Forward Ventures</td>
</tr>
<tr>
<td>Bing Yuan</td>
<td>Executive Director, Life Cycle Strategy, Novartis</td>
</tr>
</tbody>
</table>

**PLUS! PERSPECTIVES FROM:**

- Aisling Capital
- FTI Consulting
- Booz & Company
- Cerulean Pharma, Inc.
- Denovo Biomarkers
- Eisai Inc.
- Johnson & Johnson Innovation Center
- Kowa Pharmaceuticals America, Inc.
- SmartPharma
- University of Pennsylvania
- Value Creation Associates

**REGISTER BY JANUARY 25, 2014 AND SAVE $300!**
TUESDAY, APRIL 8, 2014
IN-CONFERENCE WORKSHOP

FINANCIAL PROJECTIONS AND FORECASTS TO MAXIMIZE ROI

7:30  Workshop Registration and Continental Breakfast

8:30  Workshop Leader’s Welcome and Opening Remarks

Workshop Objective:
Pharmaceutical executives seek greater transparency in R&D decision-making against the backdrop of the US fiscal cliff, changing patterns of demand, slashed budgets and the effects of the Affordable Care Act. This workshop equips executives with models for success.

Key Questions to Be Addressed:
• How to validate unmet needs?
• What early stage decisions can be made to drive future ROI?
• Should ROI be used to drive R&D decision-making?
• How should financial projections be used for financing and deal-making?
• When is partnering the right decision for biotech or pharma pipeline?

Workshop Outline:
I. Incorporating ROI into R&D Prioritization and Decision-Making
   • Learn elements of ROI analysis — Market-sizing, net present value and probability of success
   • Discuss risks and potential pitfalls of using early ROI calculations in R&D decision-making
   • Test the market — Generating viable assumptions for ROI analysis

II. Models for Success
   • Case studies on past performance
   • Lean and mean — How to improve ROI
   • Thinking outside the box

III. Analyzing the Numbers
   • Measuring the returns — Is innovation improving R&D bottom line?
   • Does collaboration improve ROI?
   • Future forecasts

12:00  Close of Workshop

There will be a 30-minute networking and refreshment break at 10:00 a.m.

Workshop Leaders:
Katie MacFarlane serves as Chief Commercial Officer at Agile Therapeutics, where she has headed commercial operations since 2010. She is also Managing Partner of SmartPharma LLC. Before joining Agile Therapeutics, Ms. MacFarlane served as President and Chief Executive Officer at Xntria Pharmaceutical Corporation, a start-up company in the development of berberine for treatment of dyslipidemia and Type II diabetes from 2006 to 2008. Prior to that, Ms. MacFarlane served as Vice President of Women’s Health and New Product Planning at Warner Chilcott, an international pharmaceutical company focused on women’s healthcare, dermatology and urology from 2001 to 2006. Ms. MacFarlane received her Bachelor of Science degree in Pharmacy and Doctor of Pharmacy degree from Purdue University. She completed a Postdoctoral Fellowship in Industrial Pharmacy Practice with Rutgers University and Hoffmann-LaRoche.

Stacey Seltzer serves as a Principal of Aisling Capital. Previously, Ms. Seltzer was at Schering-Plough, where she held roles in business development, marketing and sales, most recently serving as the US Schering-Plough Brand Lead for Zetia. Prior to Schering-Plough, Ms. Seltzer was the Director of Business Development for Acelbi, a biotechnology company developing cell-based microarrays. Ms. Seltzer began her career as a management consultant for McKinsey & Company. Ms. Seltzer serves as a director of Miramar Labs, is the Aisling representative for its investment in Precision Dermatology and serves as a board observer for Durata Therapeutics and Agile Therapeutics. She was previously a board observer for Zeltiq Aesthetics (NASDAQ: ZLTQ). Ms. Seltzer received her M.B.A. from The Wharton School at the University of Pennsylvania, where she was a Palmer Scholar. She received her M.S. and B.S. from Yale University, awarded cum laude in Molecular Biophysics and Biochemistry.
Day One  Tuesday, April 8, 2014

12:45  Chairman’s Opening Remarks
Ian Lauf, Associate Director Clinical Alliance Management, Eisai Inc.

1:00  R&D at a Crossroads — Choosing the Right Path
Manage the innovation landscape shifts and changes before they manage you. The time, cost and risk of bringing a drug to market remains a formidable hurdle to clear. Learn how to best move forward without breaking the bank.
• Navigating the evolving innovation landscape
• Identifying and managing sources of portfolio risk
• Evaluating outsourcing and risk-sharing models
• Effectively managing increasingly complex collaboration networks
Kenneth I. Kaitin, Ph.D, Director, The Tufts Center for the Study of Drug Development

Open Innovation Pioneers — Today’s Models for Future R&D ROI

1:45  KEYNOTE ADDRESS
Open Innovation — The Future of Drug Development
The Big Pharma financial model is not sustainable. The growth of R&D has outpaced sales growth, yet the output of new medicines has not increased. This Keynote Address brings the future model of drug development directly to you.
• Harness crowdsourcing to deliver promising drugs to market
• Build credibility with diverse stakeholders and produce better results
• Leverage advances in information technology and mobile health
• Lower financial risk and increase financial return
Tomasz Sablinski, M.D., Ph.D., Co-Founder, Chief Executive Officer, Transparency Life Sciences; Managing Director, Head of Clinical Development, Auven Therapeutics

2:30  Networking and Refreshment Break

3:00  How New Research Suggests Better Ways to Manage Risk and Pipeline
The pharmaceutical industry is in a severe innovation crisis. Learn how to translate the wealth of data we have today to improve the model for tomorrow.
• Rethink the pharmaceutical business model
• Hack through the assumptions, theories and fads that have stunted innovation
• Review key changes that need to be made to assure survival
• Explore the future of open innovation
Standish Fleming, Managing Member, Forward Ventures

3:45  Innovative Approaches to Source the Next, Best Drug Candidate
With a proliferation of technologies and data at a time when R&D output is slowing, the stakes are high for pharma and biotech portfolio executives to source the next best drug candidate. This session provides the necessary tools to help you access shared knowledge through open innovation, sift through alternative collaboration models, and make smart early stage investment decisions.
• Choose the right collaborative innovation model for your portfolio
• Leverage creative collaboration and transaction models to access early stage assets
• Asset-option, corporate venture, academic partnering and open innovation models
• Identify the highest value programs and partners to extend your R&D portfolio
Kenneth I. Kaitin, Ph.D, Director, The Tufts Center for the Study of Drug Development

Troy Norris, Managing Director, Valamont Advisors, LLC

5:30  Close of Day One

Networking, Wine and Cheese Reception
Immediately following the final session on day one
DAY TWO
WEDNESDAY, APRIL 9, 2014

7:30 Continental Breakfast

8:00 Chairman’s Review of Day One
Ian Lauf, Associate Director Clinical Alliance Management, Eisai Inc.

New Models for Partnerships and Collaborations to Minimize Risk and Maximize R&D Returns

8:15 INDUSTRY DISCUSSION
The Economics of Collaboration — Industry Perspectives on Maximizing the Value of R&D Collaborations

Bring partnering to the next level by minimizing risk and expense. Learn from industry executives ways to increase efficiency and trim the fat.
• Get the most return by leveraging investments
• Deliver value for both parties
• Bridge the funding gap at early stages of the partnering spectrum
• Learn best practices on up-front, royalty and milestone payments

Michael Haller, Ph. D., Chief Operating Officer and Board Director, Denovo Biomarkers
Linda Smibert, Senior Director, Operations and Business Development, Kowa Pharmaceuticals America, Inc.
Michelle Browner, Partnership and Portfolio Management, Johnson & Johnson Innovation Center, Boston

9:00 Best Practices and Strategies for Academia Collaborations and Alliances

This panel discussion delves into strategies for effectively tapping into innovation within the academic research segment. Learn how to meet expectations and avoid pitfalls when striking a deal with academia.
• Understand the governance of an academic collaboration
• Use academic innovation to bolster pipeline
• Avoid common stumbling blocks
• Learn how transparency and people management equals success
• Learn how to align your goals and incentives

Moderator: Cameron Durrant, President and Chief Executive Officer, ECR Pharmaceuticals
Panelists: Annlouise Goodermuth, Director, Alliance Management Strategy, External Innovation and Science Policy, Sanofi-Aventis
Simon Bateman, Executive Director, Global Strategic Alliance Management, Novartis
Dana Hammill, Director, Alliance Management, Translational Research Program, University of Pennsylvania

9:45 Improve the Outsourcing Model — Improve Efficiency and Accelerate Cycle Times

Outsourcing drug research and development is more important than ever. Learn from an expert on best practices to make it work.
• Learn the importance of aligning goals with CRO partners
• Understand the value of incentives and penalties to guarantee a strong ROI
• The art of managing relationships
• Avoid the temporary staff trap

Ian Lauf, Associate Director Clinical Alliance Management, Eisai Inc.

10:30 Networking and Refreshment Break

Panel: Decision-Making and Investment Prioritization

11:00 Wall Street Insights on Investment Decisions in a Crowded Market — Assess and Adjust

Learn how to read the tea leaves. Putting today’s landscape in context to help navigate the future — this session tracks trends and exposes opportunity.
• How to make investment decisions in a crowded space
• Indication selection — Business vs. analytics
• How to get in on a growing market
• How do biosimilars fit into your portfolio
• What is the future of generics

Barbara Ryan, Managing Director, FTI Consulting

11:45 Portfolio Management that Drives Value and Balances Risk and Return

Learn how to streamline your portfolio process and make it work optimally.
• Become an effective portfolio manager
• Create a well-designed, efficient and effective process
• Develop strong portfolio management practices

Michael Menke, Ph. D., Adjunct Professor, Engineering and Technology Management, Portland State University; President, Value Creation Associates

12:30 Luncheon
1:45  **Forward Approaches to Portfolio Metrics, Analytics and Project Prioritization**

The link between strong innovation and portfolio performance is clear. This session presents next-generation approaches and models for leveraging forecasting and key metrics to ensure your portfolio outperforms expectations.

- Link portfolio management and other key innovation activities
- Understand how to sharpen portfolio decision making throughout the process
- How to move the needle on ROI with better investment resource decisions
- Discuss investing metrics and tracking tools to measure return on portfolio assets

*Alex Kandybin, Partner, Booz & Company*

---

2:30  **Use Technical Innovation to Maximize Molecules and Magnify Markets**

Explore how incremental investments in technical innovation can enhance molecules' clinical profile, enable new clinical indications, increase patient acceptance and adherence and extend the life of brands.

- Use new technologies to optimize products’ pharmacological and clinical profile
- Enable new indications and widen therapeutic windows through targeted delivery
- Enhance pills and packaging to drive, differentiate and defend new markets
- Modify molecules to create next generation chemical entities
- Achieve full potential with difficult compounds

*Troy Norris, Managing Director, Valamont Advisors, LLC*

*Bing Yuan, Ph.D., Executive Director, Life Cycle Strategy, Novartis*

---

3:15  **Close of Conference**
R&D OPEN INNOVATION AND PORTFOLIO OPTIMIZATION

Lean Resource Allocation, Next-Generation Partnership Models and Investment Decision Strategies for High Return R&D

APRIL 8-9, 2014 • DOUBLETREE BY HILTON • PHILADELPHIA, PA

4 WAYS TO REGISTER NOW!

WEBSITE
www.cbinet.com/portfolio

E-MAIL
cbireg@cbinet.com

PHONE
800-817-8601
339-298-2100 outside the U.S.

LIVE CHAT
www.cbinet.com/portfolio

Register by January 25, 2014 and SAVE $300. Fee includes continental breakfast, lunch, wine and cheese reception, refreshments and conference documentation. Please make checks (in U.S. funds drawn on a U.S. bank) payable to: CBI. (No personal checks accepted.) PLEASE NOTE: All advertised discounts are taken from the final, Standard Rate.

TEAM DISCOUNT:
Attend this conference FREE if you bring 3 registered colleagues from your organization or external to your organization (enables cross-company teams). All team registrations must be made at the same time to qualify. Please contact 800-817-8601 for further information.

SATISFACTION GUARANTEED:
CBI stands behind the quality of its conferences. If you are not satisfied with the quality of the conference, a credit will be awarded towards a comparable CBI conference of your choice. Please contact 800-817-8601 for further information. Advanced preparation for CBI conferences is not required.

SUBSTITUTION AND CANCELLATION:
Your registration may be transferred to a member of your organization up to 24 hours in advance of the conference. Cancellations received in writing on or before 14 days prior to the start date of the event will be refunded, less a $399 administrative charge. No refunds will be made after this date; however, the registration fee less the $399 administrative charge can be credited to another CBI conference if you register within 30 days from the date of this conference to an alternative CBI conference scheduled within the next six months. In case of conference cancellation, CBI’s liability is limited to refund of the conference registration fee only. CBI reserves the right to alter this program without prior notice. Please Note: Speakers and agenda are subject to change. In the event of a speaker cancellation, every effort to find a suitable replacement will be made without notice. The opinions of the conference faculty do not necessarily reflect those of the companies they represent or CBI.

R&D Open Innovation and Portfolio Optimization

REGISTRATION FEE:

<table>
<thead>
<tr>
<th>Advantage Pricing</th>
<th>Standard</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conference and Workshop</td>
<td>$2299</td>
</tr>
<tr>
<td>Conference Only</td>
<td>$1999</td>
</tr>
</tbody>
</table>

To receive CBI’s special discounted hotel rate online or by phone, please go to:

- Online: www.cbinet.com/portfolio
- Phone reservations: 800-222-8733 and mention CBI’s R&D Open Innovation and Portfolio

Book Now! The Doubletree by Hilton Philadelphia Center City is accepting reservations on a space and rate availability basis. Rooms are limited, so please book early. All travel arrangements subject to availability.

VENUE:
Doubletree by Hilton Hotel Philadelphia Center City
237 South Broad Street
Philadelphia, PA 19107
Phone Reservations: 800-222-8733
Hotel Direct Line: 215-893-1600

ANY QUESTIONS OR TO REGISTER PLEASE CONTACT SONIA LIMA
Phone: 339-298-2142 • Fax: 781-939-2466
sonia.lima@cbinet.com

REGISTER AT WWW.CBINET.COM/PORTFOLIO • 800-817-8601